Bayer, BioNxt Solutions, Novo Nordisk – Opportunities in the healthcare industry

Bayer – Ahead of quarterly results

Bayer remains in a difficult position, mainly due to ongoing legal disputes in the US. These relate in particular to the controversies surrounding the crop protection product glyphosate and PCBs, which the Company inherited through its 2018 acquisition of Monsanto. This acquisition, which cost Bayer USD 63 billion, has led not only to legal challenges but also to financial ones. The Company's net financial debt has increased enormously as a result, preventing the Company from pursuing new growth opportunities in its pharmaceutical division. This is particularly problematic as the top-selling products Xarelto and Eylea will soon lose their patent protection.

On October 19, Bayer attracted attention with encouraging news about its Eylea 8 mg drug. A three-year extension study showed that the drug is not only effective but also safe for the treatment of diabetic macular edema (DME). The study showed that patients continue to benefit from longer treatment intervals, reducing the burden on patients and clinics. 25% of patients even achieved treatment intervals of six months. These promising results could position Eylea as the new standard in DME treatment and offer Bayer potential for future success in the ophthalmology market.

On October 15, Bayer submitted an application to the European Medicines Agency for approval of its novel drug Elinzanetant. This is designed to combat menopausal symptoms such as hot flashes without the use of hormones. The Phase III OASIS development program demonstrated the positive effect and safety of Elinzanetant. The prospect of Elinzanetant filling a large gap in the market – as up to 80% of menopausal women are affected by severe symptoms – offers Bayer the opportunity to have a new blockbuster. The quarterly figures will be presented today, November 12, which is likely to cause volatility in the share price, which is currently trading at EUR 24.23.

BioNxt Solutions – Innovative player in the life sciences sector

BioNxt Solutions has positioned itself as a dynamic life sciences accelerator focused on the development of advanced drug formulations and delivery systems. With research centers in North America and Europe, the Company is particularly committed to providing innovative drug delivery solutions. One operational focus is in Germany, while the Company's primary aim is to approve and market medical devices for European markets. BioNxt combines transdermal and orally disintegrating formulations and offers cost-effective diagnostic tests that can efficiently detect infectious diseases.

A significant milestone for BioNxt is the development of a novel Cladribine product for the treatment of multiple sclerosis (MS). The European Patent Office has recently confirmed the intellectual property rights for this innovation, paving the way for further international patent applications. The Company initiated this nationalization phase on October 29. The sublingual dosage form could be particularly advantageous for MS patients who have difficulty swallowing. Given the rapidly growing global market for MS drugs, this development promises significant potential. BioNxt is using cutting-edge technologies to secure a sustainable competitive advantage in the highly competitive pharmaceutical market.

In addition to advances in the MS field, BioNxt is expanding its portfolio with patents for sublingual cancer drugs. These are aimed at treating neurodegenerative autoimmune diseases. With planned patent protection until 2045, the Company is positioning itself to secure a long duration for these patents in several international markets. The development of these drugs could lead to significant improvements for patients with myasthenia gravis by making administration easier and thus making therapy more efficient. The share price bottomed out at CAD 0.195 in recent months and has risen in light of the positive news. Currently, a share costs CAD 0.24.

Novo Nordisk - Solid quarterly figures, but also challenges

The Danish pharmaceutical company Novo Nordisk has announced positive results from its Phase 3 ESSENCE study, which is investigating the drug semaglutide 2.4 mg in the treatment of non-alcoholic steatohepatitis (NASH). The study demonstrated significant progress in improving liver fibrosis and resolving NASH. At 72 weeks, 37% of patients treated with semaglutide showed improvement in liver fibrosis without a worsening of the disease, compared to 22.5% in the placebo group. NASH resolution was observed in 62.9% of study participants in the semaglutide group, compared to 34.1% in the control group. With this promising potential, Novo Nordisk plans to submit marketing authorization applications in the US and EU in the first half of 2025.

Novo Nordisk delivered solid financial results for the third quarter. Sales increased by 23% in Danish kroner to DKK 204.7 billion, while operating profit rose by 21% to DKK 91.6 billion. The North American market performed particularly well, with sales growth of 31%. The diabetes and obesity segment contributed significantly to this success, with sales growing 25% to DKK 191.8 billion. These figures reflect the sharp increase in demand for GLP-1-based treatments. Sales growth of up to 27% is forecast for the full year, supported by growing demand and the Company's innovative strength.

However, despite its success, the Company also faces challenges. Increasing competition, particularly from companies like Viking Therapeutics and Amgen, could put Novo Nordisk's market position under pressure. The introduction of generic drugs by competitors like Hims & Hers is adding to this pressure. In addition, the expiration of patents on older products is approaching, which could put pressure on margins. Analysts are concerned about the high valuation of the share compared to historical conditions. Nevertheless, optimistic voices point to the strong product pipeline and growth potential, predicting a positive future for Novo Nordisk. The share, which marked its annual high at USD 148.15 on the NYSE, has been on a downward slide since the end of June. Currently, one share costs USD 107.20.

Despite legal and financial challenges, Bayer shows potential for further growth through innovative developments such as Elinzanetant and Eylea. BioNxt Solutions impresses with patented technological advances in drug delivery and sees promising prospects in the global market for MS drugs. Novo Nordisk, bolstered by solid financial results and successful studies on Semaglutide, is benefiting from rising demand for diabetes and obesity treatments. Nevertheless, the Company faces challenges from increasing competition and expiring patents. Overall, these healthcare companies offer exciting investment opportunities with varying risk profiles through innovation and market presence.